Metabolic effects of antihypertensive drugs

被引:0
作者
Suter, PM [1 ]
Vetter, W [1 ]
机构
[1] UNIV ZURICH HOSP, MED POLICLIN, DEPT MED, CH-8091 ZURICH, SWITZERLAND
关键词
hypertension; metabolic effects; dyslipidaemia; glucose intolerance;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Effects of antihypertensive drugs on metabolism: Numerous antihypertensive drugs have been reported to cause adverse metabolic effects such as glucose intolerance and abnormal lipid metabolism. Diuretics: There is a well defined relationship between diuretic treatment and impaired glucose tolerance and dyslipidaemia. These effects, which are seen with thiazide diuretics and loop diuretics but not with spironolactone, are independent of body weight but are strongly dose-related. beta-Blocking agents: beta-Blockers without intrinsic sympathomimetic activity have adverse effects on lipid metabolism, but beta-blockers with intrinsic sympathomimetic activity do not. From the metabolic point of view, the latter type of beta-blockers represent the ideal choice, but they are rarely used today. All types of beta-blockers can cause an increase in fasting blood glucose and impaired glucose tolerance. Angiotensin converting enzyme (ACE) inhibitors and calcium antagonists: Neither ACE inhibitors nor calcium antagonists show any negative effects on glucose and/or lipid metabolism. ACE inhibitors have even been shown to improve insulin sensitivity ACE inhibitors and calcium channel blockers are metabolically neutral, and there is evidence that combining an ACE inhibitor or calcium antagonist with a diuretic can reduce the adverse effects of the latter. Anti-oxidation: Some calcium antagonists show a dose-dependent anti-oxidative activity. Lacidipine has the greatest anti-oxidative activity of the commonly used calcium channel blockers. Among ACE inhibitors, only captopril has anti-oxidative activity. Other factors: Both genetic and modifiable factors may contribute to the metabolic effects of antihypertensive drugs.
引用
收藏
页码:S11 / S17
页数:7
相关论文
共 73 条
[11]  
BULPITT CJ, 1975, BRIT HEART J, V37, P1210
[12]   FREE-RADICAL SCAVENGING - A POTENTIALLY BENEFICIAL ACTION OF THIOL-CONTAINING ANGIOTENSIN CONVERTING ENZYME-INHIBITORS [J].
CHOPRA, M ;
MCMURRAY, J ;
STEWART, J ;
DARGIE, HJ ;
SMITH, WE .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1990, 18 (06) :1184-1185
[13]   ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLOROTHIAZIDE, AND TIMOLOL [J].
CHRYSANT, SG ;
BROWN, JL ;
HAGSTROM, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 23 (04) :147-154
[14]   METABOLIC CONSEQUENCES OF ATENOLOL AND PROPRANOLOL IN TREATMENT OF ESSENTIAL HYPERTENSION [J].
DAY, JL ;
SIMPSON, N ;
METCALFE, J ;
PAGE, RL .
BRITISH MEDICAL JOURNAL, 1979, 1 (6156) :77-80
[15]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AND INSULIN SENSITIVITY - METABOLIC EFFECTS IN HYPERTENSION, DIABETES, AND HEART-FAILURE [J].
DONNELLY, R .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 :S38-S44
[16]   BETA-ADRENORECEPTOR-BLOCKING AGENTS AND LIPID-METABOLISM [J].
ENGLAND, JDF ;
HUA, ASP ;
SHAW, J .
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1978, 55 :S323-S324
[17]   EFFECTS OF PRAZOSIN AND LABETALOL ON BLOOD-PRESSURE CONTROL AND BLOOD LIPID-LEVELS IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION [J].
FARRY, JP ;
FISCHL, SJ ;
TIGHE, MJ ;
KRELL, MJ .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (1B) :41-44
[18]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422
[19]   THE EFFICACY AND SAFETY OF DIURETICS IN TREATING HYPERTENSION [J].
FREIS, ED .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (03) :223-226
[20]  
GILMAN AG, 1991, PHARM BASIS THERAPEU